Bristol-Myers Squibb is to give away more medicines to uninsured US patients, Cancer Research UK tells of funding hardship, Oxford Biomedica joins a consortium to rapidly develop a vaccine, while a Korean company works on a stem cell therapy.
Bristol-Myers Squibb Co. is expanding its patient support programs to provide free access to any of its branded medicines to unemployed patients in the US who have lost their health insurance due to the COVID-19 pandemic. The company announced the expanded program on 7 April.
There are no financial requirements for eligibility into the expanded program, and patients would be asked to provide proof of...
KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
